El Vall d'Hebron Institut de Recerca (VHIR) i ZeClinics, ambdós membres de CataloniaBio & HealthTech, treballen conjuntament en el projecte NanoDIRE-CT, l'objectiu del qual és utilitzar un mètode innovador basat en nanocossos, és a dir, fragments d'anticossos de mida petita, per a la teràpia dirigida de cèl·lules mare tumorals.

The Scientific Group, a leader in the IVD industry, and Inbiomotion, member of CataloniaBio & HealthTech, a company commercializing its proprietary MAF Test® for identifying high risk early-stage breast cancer patients have signed an agreement to start marketing MAF Test® in Sub-Saharan Africa.

Inbrain Neuroelectronics has secured a loan from the European Investment Bank (EIB) for a total of 20 million euros. The biotech, member of CataloniaBio & HealthTech, led by Carolina Aguilar, will be able to advance the clinical development of its neurology R&D programmes for diseases such as Parkinson's disease, epilepsy and speech disorders.

Two of the five European companies awarded for their innovation by the European Commission (EC) are from Catalonia. These companies are Zymvol and MJN, both CataloniaBio & HealthTech members, and both recognized under the Innovation Radar Prize 2023 program organized by the European Comission and the Dealflow.eu platform. This platform identifies high-potential innovative projects among all companies that have access to European funds.

IMIDomics, a patient-centric drug discovery and development company focused on Immune-Mediated Inflammatory Diseases (IMIDs), a CataloniaBio & HealthTech member, announced that it is expanding its strategic collaboration with Bristol Myers Squibb, a global biopharmaceutical company. This expanded partnership extends the existing relationship between the two companies, advancing their shared commitment to accelerate research and development aimed at treating IMID patients.

CataloniaBio & HealthTech, conjuntament amb Kymos i LeanBox, han organitzat aquest dimarts 28 de novembre un workshop per compartir coneixements sobre com es pot aplicar la metodologia Lean als laboratoris del sector salut. La sessió ha comptat amb una taula rodona i una part més pràctica, s’ha celebrat a la seu de Kymos Group al Parc Tecnològic de Cerdanyola del Vallès, amb totes les places esgotades; hi ha participat 40 persones, procedents de 22 empreses i institucions.

Trifermed, a corporate strategy and business development firm in the health sector, and a CataloniaBio & HealthTech member, announced its expansion into North America. The company will open its headquarters in Boston, Massachusetts, and a representative office in Montreal, Canada. This expansion is a crucial part of trifermed’s strategy to extend its global influence in Biopharmaceuticals, MedTech, and Digital Health. 

ALLOX, a techbio company, announced its incorporation, as well as the successful closing of an undisclosed pre-seed financing from Asabys new fund Sabadell Asabys II. The fund has backed the company and will join a future round involving local and international investors. 

Fertypharm, member of CataloniaBio & HealthTech announces the launch of their products FertyBiotic Mulher, FertyBiotic Homem, and FertyBiotic Gravidez in Portugal this January 2024. First steps involve forging new partnerships with A. Sousa & C.ª Lda - Pharmaceutical full-line wholesaler. 

Within the framework of the Barcelona Deep Tech Summit, the second edition of the Joan Roget Awards for Knowledge Transfer was held, convened by the Department of Research and Universities through the Catalan Foundation for Research and Innovation. The Vall d'Hebron University Hospital Foundation-Institute of Research (VHIR), member of CataloniaBio & HealthTech, has been awarded in the category of Impulse for Transfer, and OneChain, a spin-off from the Josep Carreras Leucemia Research Institute, also members of CataloniaBio & HealthTech, in the category of Successful Transfer Case. In addition, the PIKSEL project of the Center for Numerical Methods in Engineering (CIMNE) and the Department of Territory of the Government of Catalonia have also been recognized for their best collaborative R+D+I work. 

Peptomyc, member of CataloniaBio & HealthTech and spin-off of the Vall d’Hebron Institute of Oncology (VHIO) and the Catalan Institute of Research and Advanced Studies (ICREA), announces that the first patient of its Phase Ib clinical trial was successfully treated with OMO-103 – the first direct pan-Myc inhibitor to have completed Phase I clinical trial last year – in combination with the standard of care (SoC) drugs gemcitabine and nab-paclitaxel. 

MiMARK Diagnostics, S.L., member of CataloniaBio & HealthTech, has successfully raised €4.22 million as seed round stage. The substantial investment will drive the development of the company's groundbreaking gynaecological diagnostics solutions, with key EU participation from the EIC Accelerator (European Innovation Council) and private investors, including Clave Capital, Nara Capital, Namarel Ventures, and WA4STEAM investing in May this year, and CDTI Innvierte, Inveready (member of CataloniaBio & HealthTech too) and Canterbury Scientific, joining later on. 

Llambric Precision, member of CataloniaBio & HealthTech, presented at Medica Düseldorf the launch of their patented surgical instrument holder, one of their new advancements in R&D. 

Almirall S.A. (BME:ALM), a global biopharmaceutical company focused on medical dermatology, announced today that the European Commission (EC) has approved EBGLYSS (lebrikizumab) for the treatment of adult and adolescent patients (12 years and older with a bodyweight of at least 40 kg) with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. Almirall will first start the commercial launch in Germany. The company will continue the rollout in further European countries throughout 2024.

Minoryx Therapeutics, a registration stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, announced the first patients have been enrolled in its US Phase 3 clinical trial (CALYX) of lead candidate leriglitazone, to treat adult male X-linked Adrenoleukodystrophy (X-ALD) patients with cerebral Adrenoleukodystrophy (cALD), an orphan indication with no alternative therapeutic options.

The third edition of the conference "Digital Transformation in Healthcare Organizations. Trends in the Health and Social Sector," organized by the Salut Empordà Foundation (FSE), member of CataloniaBio & HealthTech, on Thursday, November 16th at the Castell de Peralada, brought together over 200 people in person and another hundred following the presentations and roundtable discussions via streaming. The main themes of this year's program focused on data management, cybersecurity, and the impact of Artificial Intelligence (AI) as a new digital tool. 

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immune deficiencies, infectious diseases and checkpoint resistant cancers, and a subsidiary of Grifols, presented investigational new drug (IND)-enabling data and the clinical trial design for its first-in-human Phase 1 study evaluating the company’s oncology candidate, GIGA-564, at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting. GigaGen anticipates trial initiation in 2024. 

D-Sight, member of CataloniaBio & HealthTech, has been selected among more than 150 applications from 18 European countries as one of the most innovative and promising projects in Europe for this year’s edition of the InnoStars Awards.  Together with another 18 participants from different European countries, the spin-off company has worked diligently on conceptualizing key aspects of its business plan and advancing the preclinical development of its drug for the treatment of early stages of diabetic retinopathy. 

The company, led by Eva García Ramos, has signed an agreement with Vision Rehab Technologies, Inc. (VRTI), which will become the exclusive distributor for the development of its technology in the United States. Thus, Wivi Vision, a member of CataloniaBio & HealthTech, begins its internationalization and expects to achieve a revenue of €5 million in 2024, multiplying the current revenue by 5. 

The consultancy firm GENESIS Biomed a reference in advisory services for R&D&i projects in the biomedical sector, member of CataloniaBio &HealthTech, will close this financial year with a record turnover of €2M, 25% more than in 2022, thanks to an exclusively organic growth strategy and an ambitious national expansion plan.